Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Antibacterial Drugs: World Industry and Market Prospects 2016-2026


News provided by

Visiongain

12 Apr, 2016, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, April 12, 2016 /PRNewswire/ --

Antibacterial Drugs: World Industry and Market Prospects 2016-2026 - our new study reveals trends, R&D progress, and predicted revenues
Where is the Antibacterial Drugs market heading? Visiongain's report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 300 page report provides 124 tables and 97 figures. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antibacterial Drugs market.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
• Read full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Dr. Holger Zimmermann, Chief Executive Officer (CEO) of AiCuris Anti-infective Cures GmbH
• Discusses the dynamic of the antibacterial drugs market and the company's drug candidate, AIC499 for the treatment of Gram-negative infections.
- Dr Bruce R. Donald (Duke University) Dr Amy C. Anderson (University of Connecticut), Mr. Pablo Gainza-Cirauqui (Duke University)
• Discusses OSPREY, the protein-design algorithm to predict mutation.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets:
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Other antibiotics.

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products' sales - what's possible for those antibacterial drugs?
How will individual antibacterial drugs perform from 2016 to 2026 at world level? Our study forecasts revenues of these brands:
• Cephalosporins
- Rocephin
- Sulperazon
- Ceftin/Zinnat
- Meiact
- Flomox
- Teflaro
- Zeftera
- Ceftolozane-tazobactam
- Ceftazidime-Avibactam

• Penicillins
- Generic amoxicillin
- Augmentin
- Zosyn/Tazocin
- Unasyn
- Generic amoxicllin-clavulanic acid
- Amoxil

• Fluoroquinolones
- Avelox
- Cravit
- Vigamox
- Ciprodex
- Cipro/Cirpobay
- Geninax
- Defafloxacin

• Macrolides
- Biaxin/Clarith
- Zithromax
- Dalacin
- Dificid
- Solithromycin

• Carbapenems
- Invanz
- Merrem/Meropen
- Primaxin
- Doribax

• Other antibiotics
- Zyvox
- Cubicin
- Tygacil
- TOBI/TIP
- Solodyn
- Vibativ
- Sirturo
- Tedizolid
- Oritavancin
- Dalbavancin
- Nemonoxacin
- Surotomycin

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for 12 leading national markets from 2016-2026:
• United States (US)
• Japan
• Germany, France, the UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).
• South Korea

This chapter also provides incidence of infection and antibacterial drug consumption by country.

Leading companies and the potential for market growth
Our analyses forecasts the world market for antibacterial drug market will reach $44.13bn in 2020.

You can also see which companies hold the most potential:
• Pfizer
• Merck & Co.
• GlaxoSmithKline
• Novartis
• Bayer
• Taisho Pharmaceuticals
• AstraZeneca
• Abbott Labs
• Daiichi Sankyo

Research and development - assess innovation, trends and possibilities
Our report discusses R&D, appraising technological, clinical and commercial possibilities.
There are 19 antibacterial drugs in phase III trials. Our report discusses:
• Small Molecule Antibacterial Drugs
• Inhaled Antibacterial Drug Formulations
• Biological Antibacterial Therapeutics
• Other Classes

How the Antibacterial Drug Market report helps you
• Revenues for antibacterial drug market to 2026 - assess the overall world drugs market's potential and receive forecasted revenues.
• Products' sales to 2026 - discover the predicted revenues of Zyvox, Cubicin,and Augmentin, amongst other leading brands.
• National market forecasting to 2026 for 12 countries - explore the best regions for treatment demand, sales and growth
• R&D activities - see the progress, trends and prospects in that ophthalmic research and development, finding technological, clinical and commercial possibilities
• Leading companies - examine the participants, including Pfizer, Merck & Co., and GlaxoSmithKline.
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantage.
• Two interviews with stakeholders in the antibacterial drug market.

Our brand new survey, by our in-house UK-based analysts, provides knowledge to benefit your research, analyses, plans, decisions and proposals. It reveals information you will find nowhere else.

Our investigation provides you with definitive data, trends, opportunities and sales predictions to 2026 for the antibacterial drug market.


Companies and Other Organisations Mentioned
Abbott Laboratories
AbbVie
Achaogen
Actavis
Actelion
Affinium Pharmaceutical
AiCuris GmbH & Co. KG
Alcon
Alkem Laboratories
Allergan
Allied Pharma
ANVISA
Apotex
APP Pharmaceuticals
Aptalis Pharma
Aquapharm Biodiscovery
Aradigm
Aridis Pharmaceuticals
Ascend Therapeutics
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals
Basilea Pharmaceuticals
Bayer Laboratories
Biomax Biotechnics
Bristol-Myers Squibb
Cadila Healthcare
Calixa Therapeutics
Cardeas Pharma
Cellceutix
Cempra Pharmaceuticals
Cipla
Claris Lifesciences
Cornerstone Biopharma
Cornerstone Therapeutics
Corona Remedies
Critical Therapeutics
Cubist Pharmaceuticals
Daiichi Sankyo
Dainippon Sumitomo
Discuva
Dr. Reddy's Laboratories
Duke University
Durata Therapeutics
Eli Lilly
European Medicines Agency (EMA)
Emcure Pharmaceuticals
Eros Pharma
Food and Drug Administration (FDA)
Forest Laboratories
Furiex Pharmaceuticals
Gate Pharma
Gilead Sciences
Glenmark
GlycoVaxyn
GlaxoSmithKline (GSK)
Hetero
Hi Tech Pharma
Hikma Farmaceutica
Hospira
Insmed
Intercell
Itochu Chemical Frontier
Janssen Pharmaceuticals
Johnson & Johnson
KaloBios
Kenta Biotech
Kuhnil Pharm
Lupin
Macleod Pharmaceuticals
Medicis
MedImmune
Meiji
Melinta Therapeutics
Merck & Co.
Merlion Pharmaceuticals
Ministry of Health, Labour and Welfare (MHLW)
Michigan State University
Microlabs
MicuRx Pharmaceuticals
Mpex Pharmaceuticals
Mylan
Nabriva Therapeutics
Nalneva
Neiss Labs
Nektar Therapeutics
National Institute for Health and Clinical Excellence (NICE)
National Institutes of Health (NIH)
Novacta Biosystems
Novartis
Novexel
Optimer Biotechnology
Orchid Chemicals
Orchid Healthcare
Ortho-McNeil
Paratek Pharmaceuticals
Peninsula Pharmaceuticals
Pfizer
Pharmacia
Phico Therapeutics
Piramal Healthcare
Plenus Pharmaceuticals
Pliva
Polyphor
Procarta Biosystems
Procter & Gamble Pharmaceuticals
Ranbaxy
Redx Pharma
Roche
Roxane
R-Pharma
Sagent Pharmaceuticals
Sandoz
Sanofi
Savara Pharmaceuticals
Sawai Pharmaceutical
Schering Plough
Seika Pharma
Sequella
Shanghai MengKe Pharmaceuticals
Shionogi
Shire
Sidmak Labs
Solitaire Pharmacia
Specialised Therapeutics Australia
Sunovion Pharma
TaiGen Biotechnology
Taisho Toyama
Takeda
TAP Holdings
Targanta Therapeutics
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
Theravance
Torrent Pharmaceuticals
Trius Therapeutics
TTY Biopharma
Unichem Laboratories
University of Connecticut
Valeant Pharmaceuticals
Vansen Pharma
ViroPharma
Warner Chilcott
Watson
World Health Organization (WHO)
Wockhardt
Zhejiang Medicine Company
Zuellig Pharma
Zydus Pharmaceuticals

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100

Or click on https://www.visiongain.com/Report/1611/Antibacterial-Drugs-World-Industry-and-Market-Prospects-2016-2026

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.